Jazz Pharmaceuticals plc (NASDAQ:JAZZ) finished Friday with an addition of $0.7 to close at $144.84, an upside of 0.49 percent. An average of 469,300 shares of common stock have been traded in the last five days. There was a gain of $4.14 in the past week, and it reached a new high 22 times over the past 12 months. The last 20 days have seen an average of 583,925 shares traded, while the 50-day average volume stands at 681,972.
JAZZ stock has increased by 7.69% in the last month. The company shares reached their 1-month lowest point of $126.01 on 10/05/21. With the stock rallying to its 52-week high on 06/15/21, shares of the company touched a low of $126.01 and a high of $189.00 in 52 weeks. It has reached a new high 17 times so far this year and lost -12.24% or -$20.21 in price. In spite of this, the price is down -23.37% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
19 days have passed since Jazz Pharmaceuticals plc (JAZZ) last reported insider trading activity. COZADD BRUCE C, who is Chairman & CEO, most recently acquired $6,598 shares at $129.87 per share on Oct 04. In this transaction, the insider spent $856,903. SVP, Technical Operations, Larkin Finbar, disposed of 63 shares at a price of $134.51 on Sep 08. The insider now owns more than $8,474 worth of shares. Prior to that, Chairman & CEO COZADD BRUCE C went on to Sale 500 shares at $131.58 each on Sep 01. An amount of $65,790 was transacted.
Jazz Pharmaceuticals plc (JAZZ) has a trailing price-to-earnings (P/E) ratio of 153.43, which compares with the 34.65 for the broader industry and 33.43 for the sector. In the last five years, Jazz Pharmaceuticals plc’s PE ratio has ranged between 194.52 and 9.642. The stock’s beta is 0.93. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.30, the price-to-book (PB) ratio at 2.08, and the price-to-cash flow ratio at 11.49.
The quick ratio of Jazz Pharmaceuticals plc for the three months ended June 29 was 1.90, and the current ratio was 3.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.57 and a total debt to equity ratio of 1.63 for the quarter ending June 29. Its gross profit as reported stood at $2.21 billion compared to revenue of $2.36 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Jazz Pharmaceuticals plc’s return on assets was 0.50%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Jazz Pharmaceuticals plc had $1.85 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$210.76 million in the quarter, while revenues of $73.99 million were grew 140.43%. The analyst consensus anticipated Jazz Pharmaceuticals plc’s latest quarter earnings to come in at $3.43 per share, but it turned out to be $3.9, a 13.70% surprise. For the quarter, EBITDA amounted to $62.04 million. Shareholders own equity worth $61.15 million.
From a technical analysis perspective, let’s take a brief look at Jazz Pharmaceuticals plc (JAZZ) price momentum. RSI 9-day as of the close on 22 October was 69.65%, suggesting the stock is Neutral, with historical volatility in this time frame at 21.26%.
As of today, JAZZ’s price is $143.80 +2.94% or $4.14 from its 5-day moving average. JAZZ is currently trading +7.01% higher than its 20-day SMA and -16.67% lower than its 100-day SMA. However, the stock’s current price level is -0.56% below the SMA50 and -11.10% below the SMA200.
The stochastic %K and %D were 91.40% and 92.88%, respectively, and the average true range (ATR) was 3.53. With the 14-day stochastic at 91.19% and the average true range at 3.63, the RSI (14) stands at 63.88%. The stock has reached 4.15 on the 9-day MACD Oscillator while the 14-day reading was at 6.12.
The consensus rating for Jazz Pharmaceuticals plc (JAZZ) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JAZZ, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 16 others rate it as a “buy”.
What is JAZZ’s price target for the next 12 months?
Analysts predict a range of price targets between $172.00 and $250.00, with a median target of $205.00. Taking a look at these predictions, the average price target given by analysts for Jazz Pharmaceuticals plc (JAZZ) stock is $205.47.